NCT05678933View on ClinicalTrials.gov

AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2029

Conditions
Peripheral T-cell Lymphoma Targeted Therapy
Interventions
DRUG

Azacitidine

Azacitidine (75mg/ m2) will be administered at day 1-5 by subcutaneous injection of each 21-day cycle.

DRUG

Chidamide

Chidamide (20 mg) will be taken orally twice a week for two weeks of each 21-day cycle.

DRUG

Cyclophosphamide

Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.

DRUG

Epirubicin

Epirubicin (70mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.

DRUG

Vincristine

Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle.

DRUG

Prednisone

Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle.

Trial Locations (1)

300060

Tianjin Medical University Cancer Insititute & Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER